FDA Taking Closer Look at Manufacturers’ Visual Testing Programs While USP Would Set New Limits for Particles

FDA investigators are taking a closer look at parenteral manufacturers’ inspections for visible particles while a proposed USP standard would give more guidance – and much needed clarity – on establishing acceptable quality limits for particles and setting up visual inspection programs.